Recursion Pharmaceuticals, Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
-2.22
Forward P/E Ratio
-3.70
PEG Ratio
0.04
-1.73
Price-to-Sales (TTM)
22.28
1.47
2.14
Market Cap
1.68B
974.88M
Is it profitable?
Net Profit Margin (TTM)
4.45%
Gross Profit Margin
59.62%
Diluted EPS (TTM)
-1.44
-59.54%
74.68M
Is it growing?
681.70%
683.66%
Is it risky?
1.01
6.89
5.50
77.97M
Who owns it?
64.39%
2.86%
34.89%
528.18M
510.32M
Does it pay?
0.00%
0.00%
--
--
How much cash?
743.29M
-371.81M
-208.52M
1.41
- Price
- 3.39
- Percent Change
- +0.20 (6.27%)
- Previous Close
- 3.19
- Open
- 3.39
- Low
- 3.29
- High
- 3.46
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$3.39
From 52W Low
+21.07%
From 52W High
-52.79%
Today
+6.27%
1Y Change
-27.10%
6M
$5.91
3M
$4.66
1M
$3.51
Today
$3.39
From 52W Low
+21.07%
From 52W High
-52.79%
Today
+6.27%
1Y Change
-27.10%
6M
$5.91
3M
$4.66
1M
$3.51
Today
$3.39
Cheap
within its 1-year price range
$3.39
Multi-Timeframe Analysis (MTA)
Strong Downtrend
All four timeframes point down. This is the strongest bearish signal. Persistent negative momentum across all periods has historically signalled continued selling pressure. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-3.4%
3M
-27.3%
6M
-42.6%
1Y
-27.1%
Rate of Change (ROC)
Decelerating
Price is falling, but slower than its usual pace. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Recursion Pharmaceuticals, Inc.
- Founded
- Jan 1, 2013
- Founders
- Blake Borgeson, Dr. Christopher C. Gibson Ph.D., Dean Li
- CEO
- Najat Khan
- Employees
- 600
- Fiscal Year End
- Dec 31, 2025
- Address
41 S Rio Grande Street
Salt Lake City
Utah
84101
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.recursion.com
Indicators
Operating Cash Flow
-371.81M
Net Income
-644.76M
Mixed Signal
0.58
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Indicators
Operating Cash Flow
-371.81M
Net Income
-644.76M
Mixed Signal
0.58
Cash flow is meaningfully below reported profit. Some gap is normal, but a persistent gap warrants questioning of the accounting.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
-2.22
Forward P/E Ratio
-3.70
PEG Ratio
0.04
-1.73
Price-to-Sales (TTM)
22.28
1.47
2.14
Market Cap
1.68B
974.88M
Is it profitable?
Net Profit Margin (TTM)
4.45%
Gross Profit Margin
59.62%
Diluted EPS (TTM)
-1.44
-59.54%
74.68M
Is it growing?
681.70%
683.66%
Is it risky?
1.01
6.89
5.50
77.97M
Who owns it?
64.39%
2.86%
34.89%
528.18M
510.32M
Does it pay?
0.00%
0.00%
--
--
How much cash?
743.29M
-371.81M
-208.52M
1.41
- Price
- 3.39
- Percent Change
- +0.20 (6.27%)
- Previous Close
- 3.19
- Open
- 3.39
- Low
- 3.29
- High
- 3.46
52-Week Range Position (52WRP)
Cheap
Cheap
within its 1-year price range
$3.39
From 52W Low
+21.07%
From 52W High
-52.79%
Today
+6.27%
1Y Change
-27.10%
6M
$5.91
3M
$4.66
1M
$3.51
Today
$3.39
From 52W Low
+21.07%
From 52W High
-52.79%
Today
+6.27%
1Y Change
-27.10%
6M
$5.91
3M
$4.66
1M
$3.51
Today
$3.39
Cheap
within its 1-year price range
$3.39
Multi-Timeframe Analysis (MTA)
Strong Downtrend
All four timeframes point down. This is the strongest bearish signal. Persistent negative momentum across all periods has historically signalled continued selling pressure. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-3.4%
3M
-27.3%
6M
-42.6%
1Y
-27.1%
Rate of Change (ROC)
Decelerating
Price is falling, but slower than its usual pace. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Recursion Pharmaceuticals, Inc.
- Founded
- Jan 1, 2013
- Founders
- Blake Borgeson, Dr. Christopher C. Gibson Ph.D., Dean Li
- CEO
- Najat Khan
- Employees
- 600
- Fiscal Year End
- Dec 31, 2025
- Address
41 S Rio Grande Street
Salt Lake City
Utah
84101
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.recursion.com